Timothy P. Noyes - Dec 1, 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Dec 1, 2022
Transactions value $
-$237,900
Form type
4
Date filed
12/2/2022, 06:00 PM
Previous filing
Nov 3, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $32.1K +15K $2.14* 15K Dec 1, 2022 Direct F1
transaction AVTE Common Stock Sale -$270K -15K -100% $18.00 0 Dec 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -15K -3.04% $0.00 478K Dec 1, 2022 Common Stock 15K $2.14 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022.
F2 A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.